Comprehensive Report on HRS-7535: An Investigational Oral Small Molecule GLP-1 Receptor Agonist

I. Introduction

HRS-7535 is an investigational oral small molecule therapeutic agent currently under development. It functions as a glucagon-like peptide-1 receptor (GLP-1R) agonist, a class of drugs that has demonstrated significant efficacy in the management of metabolic disorders.[1] The primary therapeutic areas targeted for HRS-7535 include type 2 diabetes mellitus (T2DM), for which it is in Phase 3 clinical trials, and obesity, with Phase 2 trials planned.[1] There is also an indication of potential development for diabetic nephropathy.[1] The development of an orally administered GLP-1R agonist like HRS-7535 is of considerable interest, as it offers a potential alternative to the predominantly injectable formulations currently available in this therapeutic class, which could enhance patient convenience and adherence. This report aims to provide a comprehensive overview of HRS-7535, encompassing its drug profile, mechanism of action, pharmacokinetic properties, clinical development program, safety and tolerability, efficacy findings, and future outlook.

II. Drug Profile of HRS-7535

A. Basic Information

HRS-7535 is identified as a small molecule drug.[1] It is also known by the synonyms KAI 7535 and KAI-7535.[1] The originator organization for HRS-7535 is Shandong Suncadia Medicine Co., Ltd..[1] Jiangsu Hengrui Medicine Co., Ltd. is listed as a developer alongside Shandong Suncadia Medicine.[2] Kailera Therapeutics, Inc. is also mentioned as an active organization involved with HRS-7535.[1] The relationship between these entities suggests a collaborative development effort, potentially with Shandong Suncadia leading early discovery and Jiangsu Hengrui, a major pharmaceutical entity [3], spearheading broader development and clinical trials, possibly with Kailera Therapeutics involved in specific aspects or regions.

B. Chemical and Pharmaceutical Properties

HRS-7535 belongs to the chemical class of small molecules and is categorized therapeutically as an antihyperglycaemic and an obesity therapy agent.[1] It is formulated as an oral tablet (PO) for administration.[2] HRS-7535 is classified as a New Molecular Entity (NME) [1], indicating its novel chemical structure and potential for new therapeutic effects. Currently, it does not hold an Orphan Drug Status designation.[1]

III. Mechanism of Action

A. Target Receptor

The primary molecular target of HRS-7535 is the glucagon-like peptide-1 receptor (GLP-1R).[1] The GLP-1R is a class B G protein-coupled receptor (GPCR) predominantly expressed in pancreatic beta cells, brain, heart, and gastrointestinal tract, among other tissues.[4]

B. Action

HRS-7535 functions as an agonist of the GLP-1R.[1] As a small molecule agonist, it is designed to mimic the effects of the endogenous GLP-1 hormone by binding to and activating the GLP-1R.[4]

C. Pharmacological Effects of GLP-1R Agonism

Activation of the GLP-1R by agonists like HRS-7535 elicits a cascade of physiological responses beneficial for metabolic control. These effects are well-documented for the GLP-1RA class and include:

• Stimulation of insulin secretion: GLP-1R activation on pancreatic β-cells potentiates glucose-dependent insulin secretion, meaning insulin release is augmented primarily when blood glucose levels are elevated, thereby minimizing the risk of hypoglycemia.[4]
• Inhibition of glucagon secretion: Agonism at GLP-1R on pancreatic α-cells suppresses glucagon release, also in a glucose-dependent manner. Reduced glucagon levels lead to decreased hepatic glucose production.[4]
• Delayed gastric emptying: GLP-1RAs slow the rate at which food transits from the stomach to the small intestine, which can contribute to a more gradual postprandial glucose rise and increased satiety.[4]
• Increased satiety and reduced food intake: Activation of GLP-1Rs in the brain, particularly the hypothalamus, promotes feelings of fullness and reduces appetite, leading to decreased caloric intake.[4]
• Weight reduction: The combined effects on appetite, food intake, and potentially energy expenditure contribute to body weight loss, a significant benefit for individuals with T2DM and/or obesity.[1]
• Potential cardiovascular and renal benefits: The GLP-1RA class has demonstrated cardiovascular and renal protective effects in numerous clinical trials, making them valuable for patients with T2DM at high risk for these complications.[5] While specific data for HRS-7535 in these areas are pending, its mechanism aligns with these potential benefits.

D. Significance of an Oral Small Molecule GLP-1RA

The development of orally bioavailable, small-molecule GLP-1RAs like HRS-7535 signifies a notable progression in the treatment landscape for metabolic diseases.[4] Peptide-based GLP-1RAs, while highly effective, predominantly require subcutaneous injection, which can be a barrier to initiation and long-term adherence for some patients.[5] An oral formulation offers enhanced convenience and patient preference. Small molecules, by their nature, often possess properties such as better tissue permeability and potentially different metabolic pathways compared to large peptides, which can influence their pharmacokinetic and pharmacodynamic profiles.[5] Furthermore, small molecules may offer greater flexibility for the development of fixed-dose combination tablets with other oral antidiabetic or metabolic drugs, simplifying treatment regimens. The pursuit of HRS-7535 as an oral agent aims to harness the established benefits of GLP-1R agonism while improving the ease of administration, potentially leading to broader patient access and improved long-term management of T2DM and obesity.

IV. Pharmacokinetics

The pharmacokinetic (PK) profile of HRS-7535 has been investigated in Phase 1 clinical trials involving healthy participants. These studies typically include single-ascending dose (SAD), food effect (FE), and multiple-ascending dose (MAD) components to characterize the drug's absorption, distribution, metabolism, and excretion (ADME) properties, as well as its safety and tolerability.[1]

A. Phase 1 Study Design

The Phase 1 trial for HRS-7535 comprised three parts [1]:

1. Single-Ascending Dose (SAD) Part: Healthy participants were randomized (6:2) to receive single oral doses of HRS-7535 (15 mg, 60 mg, and 120 mg) or placebo.
2. Food Effect (FE) Part: Participants were randomized (8:2) to receive a single 90 mg dose of HRS-7535 or placebo, under both fed and fasted conditions, to assess the impact of food on its absorption.
3. Multiple-Ascending Dose (MAD) Part: Participants were randomized (18:6) to receive daily oral doses of HRS-7535 (120 mg, administered using a 30/60/90/120 mg titration scheme) or placebo for 28 days.

B. Absorption and Bioavailability

Following oral administration in the SAD part, the median time to reach maximum plasma concentration (Tmax​) for HRS-7535 ranged from 5.98 to 5.99 hours across the 15 mg, 60 mg, and 120 mg doses.[1] In the MAD part, on day 28, the median Tmax​ for the 120 mg titrated dose was observed to be between 5.98 and 10.98 hours.[1] The specific impact of food on the PK parameters from the FE study (90 mg dose) was not detailed in the available abstract.[1]

C. Distribution

Specific data regarding the volume of distribution or tissue penetration of HRS-7535 are not provided in the currently available research snippets.

D. Metabolism

Details concerning the metabolic pathways and metabolites of HRS-7535 are not available in the reviewed materials.

E. Elimination

In the SAD part of the Phase 1 study, the geometric mean terminal elimination half-life (t1/2​) of HRS-7535 ranged from 5.28 to 9.08 hours across the tested doses.[1] In the MAD part, on day 28, the geometric mean t1/2​ for the 120 mg titrated dose was between 6.48 and 8.42 hours.[1] This half-life supports the potential for once-daily oral administration, a key characteristic for chronic disease management as it enhances patient convenience and is likely to improve adherence compared to injectable therapies or oral medications requiring more frequent dosing.

F. Dose Proportionality

The pharmacokinetic parameters of HRS-7535 were found to be approximately dose-proportional in the Phase 1 study, suggesting that increases in dose lead to predictable and proportional increases in drug exposure.[1]

G. Food Effect

A food effect study was conducted as part of the Phase 1 trial, where participants received a single 90 mg dose of HRS-7535 or placebo in both fed and fasted states.[1] While the study was performed, the specific results detailing how food intake alters the absorption rate (Cmax​, Tmax​) or extent (AUC) of HRS-7535 were not available in the abstract. Understanding the food effect is critical for oral drugs, as it informs dosing instructions (e.g., take with or without food, or specific timing relative to meals) to ensure consistent efficacy and safety.

H. Suitability for Once-Daily Dosing

The pharmacokinetic profile observed in Phase 1, particularly the terminal elimination half-life of approximately 6.5 to 9 hours, supports the feasibility of a once-daily dosing regimen for HRS-7535.[1]

I. Hepatic Impairment Study

A dedicated clinical trial is planned or ongoing to investigate the pharmacokinetics and safety of HRS-7535 in subjects with hepatic impairment.[8]

• Objective: To compare the PK and safety of HRS-7535 in subjects with mild to moderate hepatic impairment against subjects with normal hepatic function.
• Design: This is a non-randomized study involving three patient groups: subjects with mild hepatic impairment, subjects with moderate hepatic impairment, and subjects with normal hepatic function.
• Target Enrollment: Approximately 24 participants.
• Age Range: 18 to 70 years.
• Key Eligibility Criteria: Body Mass Index (BMI) between 18 and 32 kg/m2. Exclusions include recent significant alcohol consumption or drug abuse.
• Intervention: HRS-7535 Tablets.

The proactive initiation of a hepatic impairment study is a crucial step in drug development. Liver dysfunction is a common comorbidity in individuals with T2DM and obesity, often manifesting as non-alcoholic fatty liver disease (NAFLD) or more advanced liver conditions. Understanding how HRS-7535 behaves in patients with impaired liver function is essential for determining appropriate dosing adjustments, if any, and for ensuring the drug's safety in this subpopulation. Regulatory agencies typically require such data for comprehensive drug labeling, and obtaining it early can de-risk later stages of development and potentially broaden the drug's applicability upon approval.

V. Clinical Development Program

A. Overview of Clinical Phases

HRS-7535 is progressing through a structured clinical development program.

• Phase 1: Completed in healthy volunteers, assessing safety, tolerability, PK, and initial PD effects.[1]
• Phase 2: A Phase 2 trial for obesity (NCT06820099 / HRS-7535-206) is planned by Shandong Suncadia Medicine, with an anticipated start in February 2025 in China.[2]
• Phase 3: Currently ongoing for Type 2 Diabetes Mellitus (T2DM).[1]

B. Phase 1 Studies (Healthy Volunteers)

The initial Phase 1 trial was a randomized, double-blind, placebo-controlled study that included single-ascending dose (SAD), food effect (FE), and multiple-ascending dose (MAD) components.[1] The primary endpoints focused on the safety and tolerability of HRS-7535.[1] Key findings from this study indicated that HRS-7535 possesses a pharmacokinetic profile suitable for once-daily oral dosing, with approximately dose-proportional PK.[1] A notable pharmacodynamic effect observed in the MAD part was a mean body weight reduction of 4.38 kg (6.63% from baseline) in participants receiving HRS-7535 (120 mg titrated dose) for 28 days, compared to a 0.8 kg (1.18%) reduction in the placebo group.[1] These results were published in Diabetes, Obesity & Metabolism in March 2024 and presented at the 59th European Association for the Study of Diabetes (EASD) Annual Meeting in October 2023 (Abstract #629, Wu J.).[1] The dissemination of these findings through peer-reviewed publication and presentation at a major international endocrinology conference lends credibility and allows for broader scientific scrutiny of the early data.

C. Clinical Trials in Target Indications

1. Type 2 Diabetes Mellitus (T2DM)

HRS-7535 is currently in Phase 3 development for T2DM.1

• OUTSTAND-2 Trial (Phase 3):
• Design: A randomized, double-blinded study designed to evaluate the efficacy and safety of HRS-7535.[9]
• Comparator: Dapagliflozin, an established SGLT2 inhibitor.[9] The selection of dapagliflozin as an active comparator is noteworthy. Dapagliflozin is a widely used oral antidiabetic agent with proven efficacy in glycemic control and well-documented cardiovascular and renal benefits. Comparing HRS-7535 directly against such a robust comparator, rather than solely against placebo, indicates an ambition to position HRS-7535 as a competitive, if not superior, therapeutic option for patients with T2DM inadequately controlled on metformin. Success in this head-to-head comparison, particularly if HRS-7535 demonstrates comparable or superior glycemic lowering, favorable weight effects, and a good safety profile, could significantly influence its clinical positioning and market uptake.
• Patient Population: Adult participants (18-75 years) with T2DM diagnosed for at least 3 months, inadequate glycemic control on stable metformin therapy (≥1500 mg/day for at least 8 weeks prior to screening), and HbA1c levels between 7.5% and 11.0% (inclusive) at screening.[9]
• Objective: To evaluate the efficacy and safety of HRS-7535 compared with dapagliflozin in this patient population.[9]
• Treatment Arms: The trial includes three different oral doses of HRS-7535 tablets versus dapagliflozin tablets.[9]
• Status: Recruiting (as of information associated with a September 27, 2024 start date).[9]
• Timeline: Study Start Date: September 27, 2024; Estimated Completion Date: July 18, 2026.[9]
• Target Enrollment: 800 participants.[9]
• Location: China, with Beijing Hospital listed as a participating site.[9]
• Contact: Jian Lei (jian.lei.jl9@hengrui.com).[9]

2. Obesity

The development program for HRS-7535 includes obesity as a target indication, with the highest current phase being Phase 2 (planned).1

• Planned Phase 2 Trial (NCT06820099 / HRS-7535-206):
• Sponsor: Shandong Suncadia Medicine.[2]
• Indication: Obesity.[2]
• Location: China.[2]
• Formulation: Oral tablet (PO).[2]
• Planned Start Date: February 2025.[2] The significant weight loss observed in healthy volunteers during the Phase 1 MAD study (4.38 kg, or 6.63% of baseline body weight, over 28 days) provides a strong rationale for investigating HRS-7535 specifically for the treatment of obesity.[1] This early signal of potent weight-reducing effects aligns with the known pharmacology of GLP-1RAs. The initiation of a dedicated Phase 2 trial for obesity highlights a dual-market strategy, targeting both T2DM (where weight loss is a desirable secondary benefit) and obesity as a primary indication. This approach is common for effective GLP-1RAs that demonstrate substantial weight management properties.

3. Diabetic Nephropathy

Diabetic nephropathy is listed as an "Active Indication" for HRS-7535.1 However, specific clinical trial details for this indication are not provided in the current set of research materials. The inclusion of diabetic nephropathy as a target indication is of high clinical relevance. Diabetic kidney disease is a major microvascular complication of diabetes and a leading cause of end-stage renal disease. Several GLP-1RAs have demonstrated renal protective benefits in large cardiovascular outcome trials. If HRS-7535 can substantiate efficacy in preventing the progression or treating diabetic nephropathy, it would represent a significant therapeutic advancement and a key differentiator, particularly given the high unmet need for effective renal-protective therapies in the diabetic population. This aligns with the broader therapeutic goals for modern antidiabetic agents, which extend beyond glycemic control to include end-organ protection.

4. Heart Failure with Preserved Ejection Fraction (HFpEF) and Obesity

One research snippet 11 contains a URL and title suggesting an investigation of "HRS7535" for "Heart-Failure-With-Preserved-Ejection-Fraction-and-Obesity." However, the body of this snippet refers to a different compound, "SHR-4597," also by Jiangsu Hengrui Pharma. Due to this discrepancy, it is unclear if HRS-7535 is being formally investigated for HFpEF. Further clarification would be needed to confirm this. If such an indication were pursued, it would represent an advanced development strategy targeting complex cardiometabolic conditions where GLP-1RAs have shown promise due to their pleiotropic effects on weight, inflammation, and metabolic parameters.

Table 1: Overview of Key Clinical Trials for HRS-7535

Trial Identifier/Name	Phase	Status	Indication(s)	Key Objectives	Est. Enrollment	Snippet Source(s)
Phase 1 (SAD, MAD, FE)	Phase 1	Completed	Healthy Volunteers	Assess safety, tolerability, PK, PD	N/A (completed)	1
OUTSTAND-2	Phase 3	Recruiting	Type 2 Diabetes Mellitus (with metformin)	Evaluate efficacy and safety of HRS-7535 vs. dapagliflozin	800	9
NCT06820099 / HRS-7535-206	Phase 2	Planned	Obesity	Evaluate efficacy and safety for obesity	N/A (planned)	2
Hepatic Impairment Study	Phase 1/2	N/A (likely early)	Hepatic Impairment (mild to moderate) vs. Normal HF	Compare PK and safety in hepatic impairment	24	8
Diabetic Nephropathy	N/A	Active Indication	Diabetic Nephropathy	N/A (specific trial details not yet available)	N/A	1

N/A: Not Available in provided snippets. HF: Hepatic Function.

VI. Safety and Tolerability

A. Summary of Adverse Events from Phase 1 Studies

The Phase 1 studies in healthy volunteers reported that the most frequently observed adverse events (AEs) associated with HRS-7535 were nausea and vomiting.[1] This pattern was consistent across the single-ascending dose (SAD), food effect (FE), and multiple-ascending dose (MAD) parts of the trial. Overall, HRS-7535 was described as exhibiting a safety and tolerability profile consistent with that of other GLP-1 receptor agonists.[1] More detailed information on other specific AEs or their severity beyond nausea and vomiting was not extensively provided in the publicly available abstract of the Phase 1 publication.[7]

B. Class-Specific Safety Considerations for GLP-1RAs

The GLP-1RA class is associated with a known set of potential safety considerations, which include:

• Gastrointestinal Adverse Events: Nausea, vomiting, and diarrhea are the most common AEs, particularly upon initiation and dose escalation. These are generally transient and mild to moderate in severity for most patients.
• Pancreatitis: An increased risk of acute pancreatitis has been a topic of investigation for the class, though large outcome trials have generally not confirmed a causal link for most agents; it remains a precaution.
• Thyroid C-cell Tumors: Rodent studies with some GLP-1RAs showed an increase in thyroid C-cell tumors. The relevance to humans is considered low due to species differences in C-cell biology, but it remains a warning, and GLP-1RAs are typically contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Hypoglycemia: The risk of hypoglycemia with GLP-1RAs is generally low when used as monotherapy or in combination with metformin, as their insulinotropic effect is glucose-dependent. However, the risk increases when they are co-administered with insulin or sulfonylureas.
• Injection Site Reactions: Common with injectable GLP-1RAs, though this is not applicable to the oral formulation of HRS-7535.

C. Ongoing and Future Safety Monitoring

Comprehensive safety data for HRS-7535 will emerge from the larger and longer-duration clinical trials:

• The Phase 3 OUTSTAND-2 trial in T2DM will provide extensive safety information in the target patient population, including a comparison against an active comparator, dapagliflozin.[9]
• The planned Phase 2 trial in obesity (NCT06820099) will specifically assess safety and tolerability in individuals being treated for weight management.[2]
• The dedicated hepatic impairment study will provide crucial safety data for patients with liver dysfunction.[8]

While the early safety signals for HRS-7535 appear to align with the established profile of the GLP-1RA class, particularly concerning gastrointestinal AEs like nausea and vomiting, the long-term safety and tolerability profile derived from these more extensive Phase 2 and Phase 3 trials will be critical. Given that T2DM and obesity are chronic conditions requiring long-term treatment, a favorable and manageable long-term safety record is paramount. Patient adherence can be significantly impacted by tolerability issues; thus, effective strategies for managing common side effects, alongside a low incidence of serious or unexpected AEs, will be essential for the successful adoption and market positioning of HRS-7535, especially in a competitive landscape with other available GLP-1RAs.

VII. Efficacy Findings and Therapeutic Potential

A. Early Efficacy Signals from Phase 1

The Phase 1 multiple-ascending dose (MAD) study in healthy volunteers provided an early indication of HRS-7535's pharmacodynamic activity, particularly concerning weight management. Participants receiving a daily 120 mg titrated dose of HRS-7535 for 28 days experienced a mean body weight reduction of 4.38 kg, which corresponded to a 6.63% decrease from baseline. In contrast, the placebo group showed a mean weight reduction of only 0.8 kg (1.18%).[1] This statistically and clinically meaningful weight loss in a short timeframe in healthy individuals is a robust early signal of potential efficacy for both obesity and T2DM, where weight reduction is a key therapeutic objective.

B. Endpoints for Ongoing/Planned Pivotal Trials

• OUTSTAND-2 (Phase 3, T2DM): While the primary endpoint is not explicitly stated in the snippets for OUTSTAND-2, for T2DM trials of this nature, it is typically the change in HbA1c from baseline. Secondary endpoints commonly include the change in body weight, the proportion of patients achieving specific glycemic targets (e.g., HbA1c <7.0%), changes in fasting plasma glucose, and safety/tolerability assessments.[9]
• Phase 2 Obesity Trial (NCT06820099): For obesity trials, the primary endpoint is usually the percentage change in body weight from baseline after a defined treatment period. Important secondary endpoints often include the proportion of patients achieving categorical weight loss thresholds (e.g., ≥5%, ≥10%, ≥15% weight loss), changes in waist circumference, and effects on cardiometabolic risk factors.[2]

C. Therapeutic Potential in Target Indications

• Type 2 Diabetes Mellitus: HRS-7535 holds potential as an effective oral agent for improving glycemic control and promoting weight reduction in patients with T2DM. Its utility could be as an add-on therapy to metformin, as being studied in OUTSTAND-2 [9], or potentially as an alternative to other second-line oral antidiabetic agents.
• Obesity: The significant weight loss observed in early studies positions HRS-7535 as a promising candidate for chronic weight management, offering the convenience of an oral formulation.[1]
• Diabetic Nephropathy: If efficacy in diabetic nephropathy is demonstrated in future trials, HRS-7535 would address a critical unmet medical need for patients with T2DM, potentially offering renal protection in addition to its metabolic benefits.[1]

The efficacy of HRS-7535 will inevitably be compared against a landscape of highly effective existing therapies. For T2DM and obesity, injectable GLP-1RAs (e.g., semaglutide, liraglutide) and dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) have set high benchmarks for glycemic control and weight loss. Within the emerging oral GLP-1RA space, oral semaglutide is an established comparator, and other oral small molecules like danuglipron are also in development. The ~6.6% weight loss observed with HRS-7535 in healthy volunteers over just 4 weeks is a promising initial result.[1] For T2DM, the direct comparison with dapagliflozin in the OUTSTAND-2 trial will be a crucial determinant of its relative efficacy against a different class of oral antidiabetic drugs.[9] To achieve significant market penetration, HRS-7535 will need to demonstrate not only the convenience of an oral small-molecule but also competitive efficacy in terms of HbA1c reduction and weight loss, coupled with a favorable long-term safety and tolerability profile.

VIII. Regulatory Status and Future Outlook

A. Current Regulatory Standing

HRS-7535 is currently an investigational drug and has not yet received marketing approval from any regulatory agency. It is actively undergoing clinical development.

B. Potential Timelines for Key Milestones

Based on the available information:

• The Phase 3 OUTSTAND-2 trial for T2DM is estimated to be completed by July 2026.[9]
• The Phase 2 trial for obesity (NCT06820099) is planned to commence in February 2025.[2] Submission for regulatory approvals would follow the successful completion of these pivotal trials and compilation of sufficient efficacy and safety data.

C. Market Positioning and Competitive Landscape

HRS-7535 enters a dynamic and competitive market for metabolic diseases.

• Oral Small Molecule Advantage: Its primary differentiating factor is its nature as an oral small molecule GLP-1RA, offering convenience over injectables.[1]
• Competition: It faces competition from highly efficacious injectable GLP-1RAs and dual GIP/GLP-1 agonists, as well as other oral GLP-1RAs (e.g., oral semaglutide) and agents from other classes like SGLT2 inhibitors (e.g., dapagliflozin, its comparator in OUTSTAND-2).[9]
• Importance of Broader Benefits: To compete effectively, particularly against agents with established cardiovascular and renal benefits (like many SGLT2 inhibitors and some GLP-1RAs), HRS-7535 may need to demonstrate similar long-term protective effects beyond glycemic control and weight loss. The pursuit of a diabetic nephropathy indication suggests an awareness of this need.[1]

D. Unanswered Questions and Future Research

Several areas require further data and clarification:

• Publication of full Phase 1 results, including detailed food effect data and a comprehensive adverse event profile beyond nausea and vomiting.
• Efficacy and safety outcomes from the ongoing Phase 3 T2DM trial (OUTSTAND-2) and the planned Phase 2 obesity trial, particularly in diverse patient populations.
• Specific clinical trial data supporting the potential indication for diabetic nephropathy.
• Long-term cardiovascular and renal outcomes data, which are crucial for positioning in the T2DM market.
• Potential head-to-head comparisons with other leading oral and injectable GLP-1RAs to better define its relative efficacy and safety.

A key consideration for HRS-7535 will be the balance between the convenience it offers as an oral small molecule and the ultimate efficacy it can deliver. While patients and physicians highly value the ease of oral administration, which can lead to better adherence, the treatment landscape for T2DM and obesity is increasingly characterized by therapies demonstrating very high levels of efficacy, especially potent injectables. The Phase 1 weight loss data for HRS-7535 are encouraging [1], but the results from Phase 3 trials will be definitive in establishing its comparative effectiveness. HRS-7535 will need to achieve a magnitude of treatment effect that is compelling enough for clinicians and patients to choose it, considering both its convenience and its performance against established benchmarks.

The primary development of HRS-7535 appears to be centered in China, with Shandong Suncadia Medicine and Jiangsu Hengrui Pharmaceuticals leading the efforts, and clinical trials predominantly located there.[1] Given the substantial and increasing prevalence of T2DM and obesity in China, HRS-7535 is well-positioned to address this significant domestic market need. Local development and manufacturing capabilities could provide strategic advantages. However, its broader global potential will be contingent upon the execution of international clinical trial programs, securing regulatory approvals from agencies such as the FDA and EMA, and potentially forming strategic partnerships for commercialization in regions outside of China. The involvement of Kailera Therapeutics [1] might signal such international ambitions, though further details on this collaboration would be necessary to confirm its scope.

IX. Conclusion

HRS-7535 is an investigational oral small molecule glucagon-like peptide-1 receptor agonist that holds considerable promise for the treatment of type 2 diabetes mellitus and obesity, with a potential expansion into diabetic nephropathy. Its development as an oral agent addresses a key limitation of many current GLP-1RAs, which are primarily injectable, thereby offering the potential for improved patient convenience and adherence.

Early Phase 1 clinical data have demonstrated a pharmacokinetic profile suitable for once-daily dosing and encouraging pharmacodynamic effects, notably significant weight loss in healthy volunteers.[1] The safety profile observed thus far, characterized mainly by nausea and vomiting, appears consistent with the known effects of the GLP-1RA class.[1]

The ongoing Phase 3 trial (OUTSTAND-2) in T2DM, which compares HRS-7535 to dapagliflozin, and the planned Phase 2 trial in obesity will be critical in establishing its definitive efficacy and long-term safety profile.[2] The proactive investigation in special populations, such as those with hepatic impairment, is a positive aspect of its development program.[8]

The success of HRS-7535 will depend on its ability to demonstrate a compelling balance of efficacy, safety, and tolerability in a competitive therapeutic landscape. While the convenience of an oral formulation is a distinct advantage, the magnitude of its clinical benefits, particularly in comparison to highly effective existing injectable therapies and other emerging oral agents, will ultimately determine its place in therapy. The focus on the Chinese market is clear, but its global impact will hinge on broader regulatory strategies and international clinical development. Continued research and the outcomes of pivotal trials are eagerly awaited to fully elucidate the therapeutic value of HRS-7535.

Works cited

1. HRS-7535 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed May 12, 2025, https://synapse.patsnap.com/drug/812aa6dd2c9346f4a3fb07828c4d5a80
2. HRS 7535 - AdisInsight - Springer, accessed May 12, 2025, https://adisinsight.springer.com/drugs/800068387
3. 1970 - Jiangsu Hengrui Pharmaceuticals Co., Ltd., accessed May 12, 2025, https://www.hengrui.com/en/about.html
4. A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor - PMC, accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9234956/
5. Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review | Published in Journal of Brown Hospital Medicine, accessed May 12, 2025, https://bhm.scholasticahq.com/article/132255-current-insights-advantages-and-challenges-of-small-molecule-glucagon-like-peptide-1-receptor-agonists-a-scoping-review
6. The Dramatic 24 Hours of Hengrui Pharmaceutical - Patsnap Synapse, accessed May 12, 2025, https://synapse.patsnap.com/blog/the-dramatic-24-hours-of-hengrui-pharmaceutical
7. Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a ..., accessed May 12, 2025, https://pubmed.ncbi.nlm.nih.gov/38100147/
8. Investigation of Pharmacokinetics and Safety of HRS-7535 in Subjects With Hepatic Impairment and Normal Hepatic Function - ClinicalTrials.Veeva, accessed May 12, 2025, https://ctv.veeva.com/study/investigation-of-pharmacokinetics-and-safety-of-hrs-7535-in-subjects-with-hepatic-impairment-and-nor
9. A Phase 3, Randomized, Double-blinded Study to Evaluate the Efficacy and Safety of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (OUTSTAND-2) | MediFind, accessed May 12, 2025, https://www.medifind.com/conditions/undefined/1578/clinical-trial/528839352
10. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel oral small molecule GLP-1 receptor agonist (HRS-7535) in healthy subjects - Media Centre | EASD, accessed May 12, 2025, https://www.easd.org/media-centre/#!resources/safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-a-novel-oral-small-molecule-glp-1-receptor-agonist-hrs-7535-in-healthy-subjects-6f0bab72-f018-42a8-b439-254930a810a5
11. Efficacy-and-Safety-of-HRS7535-in-for-Heart-Failure-With-Preserved-Ejection-Fraction-and-Obesity - Larvol Delta, accessed May 12, 2025, https://delta.larvol.com/Institutions/b9f2fa712ff5454da6ca457fc3f15a69/JiangsuHengruiPharma/7/6050c42de4ce47e69543fb83d2fc6dfa/Efficacy-and-Safety-of-HRS7535-in-for-Heart-Failure-With-Preserved-Ejection-Fraction-and-Obesity/